Centessa Pharmaceuticals is involved in the development of innovative new treatments. Taylor Wessing advised ApcinteX, Capella Biosciences, Inexia, LockBody Therapeutics, Morphogen-IX, Orexia, Pega-One and Z Factor on their participation in the deal.
This complex deal was led by Ross McNaughton and Ed Chapman, with IP support led by life sciences specialist Colin McCall. The transaction involved advice from across the firm’s corporate, patent, tax and incentives groups. The deal underlines the firm's strong position in the Cambridge and wider UK market, working with companies and investors in the biotech space.